Zoom Logo

What’s New in Contraceptive R&D Investments and Resources? - Shared screen with speaker view
Moderator
41:58
Thank you for joining! While we’re waiting, feel free to introduce yourself in the chat with your name, organization, and where you’re joining us from.
Saumya RamaRao
42:49
Saumya RamaRao from the Population Council. Also Chair of the NURHT Caucus of the RHSC
Fatou Jallow
43:04
Good morning. Fatou Jallow from USAID
Sara Stratton
43:19
Good morning, Sara Stratton, Palladium
Kirsten Vogelsong
43:26
Hello - this is Kirsten Vogelsong from the Bill & Melinda Gates Foundation. I'm so glad to be part of this event and to welcome you all.
Moderator
44:36
Thank you for joining! While we’re waiting, feel free to introduce yourself in the chat with your name, organization, and where you’re joining us from.
Kelly Culwell
45:01
Hello all - Kelly Culwell from Evofem Biosciences
Seth McGovern
45:04
Hello everyone, Seth McGovern from Population Services International.
Andrew Tuttle
45:11
Hi Everyone! I'm Andrew Tuttle, Director of Research at Policy Cures Research.
Rebecca Callahan
45:30
Hello everyone....this is Rebecca Callahan from FHI 360.
Greg Grover
45:31
Hi everyone, Greg Grover CTO from Contraline, Inc (male contraceptive device).
Jane Bertrand
45:37
Hi, Jane Bertrand here, Tulane University.
Gustavo Blanco
45:41
This is Gustavo Blanco from University of Kansas in KC, thank you for including me in this presentation.
Mukul Taparia
45:42
Hi Everyone. This is Mukul Taparia from Pregna International Ltd. (manufacturer of Hormonal and Copper IUDs)
Kendal Danna
45:52
Hi All, Kendal Danna from Population Services International
Safia Ahsan
45:59
Hi all - Safia Ahsan from RH Supplies Coalition
Anna Doubell
46:01
hi! Anna Doubell, COO of Policy Cures Research, calling in from Australia
Ajit Raje
46:02
Ajit Raje to from Pregna International, hello everyone
Jennifer Gassner
46:06
Hi, Jen Gassner from MSI
Beth Fredrick
46:24
Beth Fredrick, Johns Hopkins, Advance Family Planning.
Navita Jain
46:27
Hi everyone, this is Navita Jain from AVAC
GREGORY S KOPF
46:36
Greg Kopf of FHI360
Katie Williams
46:43
Hi all! Katie Williams, FHI 360/UNC
Reana Thomas
47:26
Hello! Reana Thomas from FHI 360
Wynne Boelt
47:36
Hi all, Wynne Boelt with Policy Cures Research
ali Kubba
47:49
hi this is Ali Kubba from the European Society of Contraception, special hello to David Archer
Gathari Ndirangu
47:50
Gathari Ndirangu, Pathfinder International
Katherine Hamil
47:51
Katherine Hamil from Eppin Pharma Inc
Megan Christofield
47:54
hi all! Megan Christofield, Jhpiego
Peter Hall
47:55
Greetings to many old friends
Levent Çağatay
47:59
Hello All, Levent Cagatay from EngenderHealth
Frederik Madsen
47:59
Hi everyone, Frederik Petursson Madsen from Cirqle Biomedical
Frederik Madsen
48:05
Hi! I’m Thomas Crouzier, from Cirqle Biomedical
Agnes Chidanyika
48:07
Hello everyone! Agnes Chidanyika from UNFPA
Neeta Bhatnagar
48:08
Hello all, Neeta Bhatnagar, Jhpiego
Martha Brady
48:09
hello everyone! Martha Brady, Director of Sexual and Reproductive Health, PATH
Chelsea Polis
48:09
Hi all! Chelsea Polis, Guttmacher Institute.
Kirsten Krueger
48:25
Hello! Kirsten Krueger Technical Advisor Research Utilization, FHI 360 - North Carolina
Martyn Smith
48:30
Hello everyone, Martyn Smith, Managing Director FP2020 here.
Deborah O'Brien
48:45
Hi to everyone! Debbie O’Brien
Moderator
48:55
Please keep yourself on mute and your video off during the event.
Moderator
49:02
Send us any questions here to the chat box, and we’ll answer them during the panel discussion and Q&A at the end.
Moderator
49:11
In case you encounter any technical difficulties, we’re recording the event and will share the recording with everyone registered.If you don’t have audio right now: (1) check your settings to confirm you’re connected to your computer’s speakers or headphones via the arrow showed on the slide that’s next to your microphone on/off, or (2) you can always dial in via phone for audio. You’ll need the Meeting ID (940 2125 3918) and the password from the registration (396959). Dial-in numbers can also be found in the registration email.
David Archer
49:38
Good day to everyone, David Archer
Moderator
49:51
For more information on Policy Cures Research, visit https://www.policycuresresearch.org or follow them on Twitter @PCuresResearch.
Moderator
50:16
For more information on the CTI Exchange, visit https://www.ctiexchange.org or follow them on Twitter @CTIExchange.
Moderator
51:17
Send us any questions here to the chat box, and we’ll answer them during the panel discussion and Q&A at the end.
Agnes Chidanyika
56:39
Any generic products in the pipeline for 1-rod contraceptive implants? Any male contraceptives in development?
Jeff Spieler
57:17
MPTs are part of contraception so it's contraception plus half the amount for MPTs that can be used to estimate the investment
Moderator
01:00:20
Link to the full 2020 G-FINDER report: https://www.policycuresresearch.org/analysisLink to the G-FINDER data portal: https://gfinderdata.policycuresresearch.org
Moderator
01:02:02
Link to the Calliope database: https://pipeline.ctiexchange.org
Moderator
01:05:16
Link to NICHD’s CTIDBase: http://www.citdbase.org
Moderator
01:05:34
Link to IMPT’s database: http://mpts101.org
Moderator
01:05:55
Link to the CTI Exchange: https://www.ctiexchange.org
Moderator
01:07:16
CTI Exchange blog series: https://www.ctiexchange.org/exchanges-seriesCTI Exchange Resource Library: https://www.ctiexchange.org/resource-library
Moderator
01:07:35
Send input and feedback to us at cti@fhi360.org
Saumya RamaRao
01:18:35
Comment: It ia indeed a movement. The Population Council's experience that it is a partnership of mission-minded orgs, industry, donors, and partners to advocate, do the research and rolling out.
Jeff Spieler
01:20:20
Kate, Please do tell us why any (about half) of the investment in MPTs was not included in the estimate of the investment in Contraceptive R&D?
Kate Rademacher
01:20:53
Got it - thanks, Jeff. I'm going to ask Maya to speak to this point
Megan Christofield
01:21:46
Is there a tipping point where public sector and philanthropic investment begins to attract Big Pharma back into the space? Is attracting them part of the aim
Moderator
01:23:01
Link to the Biology of Reproduction Contraceptive R&D special issue: https://academic.oup.com/biolreprod/issue/103/2
Moderator
01:23:29
Link to CTI Exchange blog series on non-contraceptive benefits: https://www.ctiexchange.org/post/not-all-bad-rethinking-contraceptive-side-effects
Moderator
01:23:53
Please send us your questions here in the chat box for the panel discussion and Q&A.
Martha Brady
01:23:57
Great presentations all!
Sara Stratton
01:24:10
In addition to Megan's question, how are generic manufactuerers being included in overall ecosystem?
Megan Christofield
01:26:33
I’d also be curious to hear more about how user experience is being collected and used (or how it will be)?
Mukul Taparia
01:27:43
Its important to differentiate between Development of product and regulatory approval (WHO PQ) for products. In many cases, products remain inaccessible due to the second part (regulatory approval) not being accomplished due to lack of funding.
Saumya RamaRao
01:28:53
Indeed the Population Council is researching male contraception. Nestorone® (segesterone acetate) and testosterone. NES/T is a novel, reversible contraceptive for men designed to be absorbed through the skin on the upper arms and shoulders.
Saumya RamaRao
01:29:25
A trial is currently underway: see https://www.popcouncil.org/news/first-trial-launches-to-test-effectiveness-of-male-contraceptive-gel
Edith Guilbert
01:30:26
Thank you for this gathering. Regarding non contraceptive benefits, is there new research on the effectiveness of marketing contraceptive methods on the basis of their non contraceptive benefits?
Gathari Ndirangu
01:30:30
Is there currently anything on absorbable contraceptive implants to eliminate the need for removal? There has been mention of such initiatives having been abandoned in the 70s.
Jeff Spieler
01:30:30
There was some research supported by USAID on a single rod LNG implant. It is doable.
Martha Brady
01:30:32
Must distinquish between R&D and drug development from product manufacturing.
Martha Brady
01:32:34
RSHC convene manufacturers overall. including but not only generic manufacturers
Martha Brady
01:33:28
PATH has a large body of work on human center design in our tools and devices across health programs/products (not only SRH/FP)
Avishek Hazra
01:34:12
Very pertinent point by Mukul. The funding on contraceptive R&D should give equal importance to these two integral elements - development of drug/product and regulatory approval.
Peter Hall
01:34:17
Keen to see focus on "male" methods that are female-controlled! eg, methods impacting sperm motility, spem-egg interaction, fertilization, etc.
GREGORY S KOPF
01:35:00
To Gathari
GREGORY S KOPF
01:35:26
To Gathari-FHI 360 has two biodegradable contraceptive implants in development
Megan Christofield
01:36:02
on the genetics side, new piece out on Sept issue of contraception: https://www.contraceptionjournal.org/article/S0010-7824(20)30150-5/fulltext?dgcid=raven_jbs_etoc_email
Jeff Spieler
01:36:29
My long standing hypothesis is that if we could develop a method for addressing and important health issue, like preventing HIV, STIs, breast cancer, prostate cancer and the side effect was contraception, more people would be interested in contraception.
Martha Brady
01:36:44
Great discussion and great presentations! Thanks all! Upbeat and hopeful which is sorely needed!
Anne Pfitzer
01:36:44
love the pun! Kate
Edith Guilbert
01:36:59
Completely agree Jeff.
Moderator
01:37:12
For more information on Policy Cures Research, visit https://www.policycuresresearch.org or follow them on Twitter @PCuresResearch.For more information on the CTI Exchange, visit https://www.ctiexchange.org or follow them on Twitter @CTIExchange.Thank you for joining us. We’ll share the event recording with you next week.
Sara Stratton
01:37:14
Good presentations/discussions. Thanks!
Megan Christofield
01:37:28
great webinar!!!
Chelsea Polis
01:37:33
Grateful to all of you for this incredibly important work and this great panel today!
Safia Ahsan
01:37:35
Thanks!
Jennifer Gassner
01:37:38
Interestingly Jeff, we found that cervical cancer screening led to increased uptake of IUDs in our clients - the motivation you lead with does matter!
Kirsten Krueger
01:37:40
Thanks!!
Edith Guilbert
01:37:42
Thank you
GREGORY S KOPF
01:37:44
Great set pf presentations!
Anne Pfitzer
01:37:49
thank you - great job moderating!
Jeff Spieler
01:37:50
Thank you!!!
Frederik Madsen
01:37:54
Thanks :)
Prithi Kochhar
01:37:56
this was great.. thanks everyone